Wolfe Research downgrades 89bio stock rating to Peerperform after acquisition news

Roche is acquiring 89bio Inc. for $14.50 per share in cash plus a contingent value right, potentially valuing the transaction at up to $3.5 billion, primarily for its late-stage MASH treatment, pegozafermin. Following an 85% stock surge, Wolfe Research downgraded 89bio to Peerperform, citing the acquisition as fully priced into the current share value and anticipating no regulatory hurdles. This deal, expected to close in Q4 2025, highlights the strategic interest in innovative liver disease treatments, though immediate upside for ETNB is viewed as limited by some analysts post-announcement.

Analysis

Roche's acquisition of 89bio (ETNB) for $14.50 per share in cash, plus a contingent value right (CVR) of up to $6.00 per share, has catalyzed a significant re-rating of the stock. The deal, potentially valued at up to $3.5 billion and centered on 89bio's late-stage MASH treatment pegozafermin, triggered an 85% surge in ETNB's share price over the past week to a level near its 52-week high of $15.06. This price action has led Wolfe Research to downgrade the stock from Outperform to Peerperform, positing that the current valuation fully incorporates the acquisition premium. Wolfe sees limited further upside, establishing a fair value range of $14.50 to $20.50, which covers the full cash and CVR potential. The firm assesses a low probability of regulatory hurdles, given Roche's minimal market presence in NASH, and considers the emergence of a competing bidder unlikely. Contrastingly, H.C. Wainwright initiated coverage with a Buy rating, while RBC Capital maintained a Sector Perform rating but reduced its price target to $11, reflecting mixed analyst sentiment following the announcement.

Key Decisions for Investors

• Given the stock is trading near $15.06, above the $14.50 cash offer, investors should recognize that near-term upside is now primarily tied to the speculative value of the CVR, which is contingent on future milestones.
• With the deal viewed as fully priced-in by some analysts and technical indicators suggesting overbought conditions, initiating new long positions carries a challenging risk/reward profile, as the guaranteed cash component is below the current market price.
• Investors holding positions should monitor the progress of 89bio's Phase III MASH studies and any regulatory developments ahead of the expected Q4 2025 close, as these will directly impact the CVR's value and the transaction's certainty.